Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo Healthcare to Focus on Switch OTC Drugs
April 16, 2007
- Permax Withdrawn from US Market
April 16, 2007
- TOPICS／ACNielsen, So-net M3 to Start Radar"Track Service
April 16, 2007
- Data Protection Period Extended to 8 Years
April 16, 2007
- Great Precautions Needed in Revising PMDA's Employment Rule: Health Minister
April 16, 2007
- Need for Relaxing PMDA's Employment Regulations Pointed Out
April 16, 2007
- REGULATORY NEWS IN BRIEF
April 16, 2007
- TOPICS／Wyeth Salutes WHO Call to Action to Combat Pneumococcal Disease
April 16, 2007
- EFPIA, EC Embark on Joint Drug Discovery Research Project
April 16, 2007
- Study Group on Early Approval of Safe, Effective Drugs
April 16, 2007
- 90% of Doctors Predict Increases in Cerebro-, Cardiovascular Diseases: Prof. Teramoto
April 16, 2007
- Ordinary Single-Dose Tox Studies Sufficient to Initiate MD Studies: Symposium
April 16, 2007
- Daiichi Sankyo Sets Out To Become a "Global Pharma Innovator"
April 16, 2007
- R&D NEWS IN BRIEF
April 16, 2007
- Mochida to Increase MRs to 750 by FY2009
April 16, 2007
- TOPICS／Abilify Receives PSJ Award: Otsuka
April 16, 2007
- Takeda, CanBas to Jointly Develop Anticancer Treatment
April 9, 2007
- Takeda, LGLS to Collaborate to Develop Anti-Obesity Drugs
April 9, 2007
- Takeda Acquires Full Rights to R-851 from 3M
April 9, 2007
- BI Expects Double-Digit Growth Again in 2007: Chairman Dr Banchi
April 9, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…